Study shows GHRH antagonist’s role in AML drug resistance

A new research paper was published in Oncotarget’s Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”

Implantable sensors aid in optimizing bone injury recovery

Tiny implantable sensors are helping University of Oregon researchers optimize the process of recovery from severe bone injuries.

December 12, 2024

Lilly CEO raises concerns about Novo-Catalent buy, calling the Novo Nordisk deal ‘unusual’

Eli Lilly has expressed reservations about the Novo-Catalent deal and its potential impact on the wider manufacturing industry. “Given the nature of this transaction —

February 8, 2024

Researchers develop new, modular strategy for T-cell-based immunotherapy

Immunotherapies for cancer aim to induce the immune system to combat cancer cells more effectively.

August 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.